



Nucleotides Delivery for Cancer Treatment

Guest Editor:

Dr. Anna Scomparin

Department of Drug Science and
Technology, University of Turin,
10125 Turin, Italy

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editor

Dear Colleagues,

The discovery of the RNA interference mechanism prompted the use of oligonucleotides as therapeutic agents for the treatment of several diseases, including cancer. Nevertheless, the peculiar physico-chemical features of the short RNA or DNA molecules and the complex physiopathology of tumour pose a hurdle to the efficacious delivery of oligonucleotides to cancer cells. To overcome these problems, scientists developed different types of carriers, such as viral vectors, exosomes, polymer- and lipid-based systems.

This Special Issue aims to highlight novel approaches to the delivery of oligonucleotides to cancer, with attention to all the aspects of the nanomedicine development, from their synthesis and physico-chemical characterization, to the understanding of their biological properties and the in vivo efficacy. We are looking forward to receiving original research papers as well as review articles with expert opinion on the state of art and future perspective on the field.

Dr. Anna Scomparin
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Department of Pharmaceutics,
Ernest Mario School of
Pharmacy, Rutgers University,
Piscataway, NJ 08854, USA

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1 (*Pharmaceutical Science*)

Contact Us

Pharmaceutics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/pharmaceutics
pharmaceutics@mdpi.com
X@MDPIpharma